Wong, PhD, MPH, a professor of medicine at the University of California, Irvine School of Medicine, and colleagues noted that the impact glucagon-like peptide 1 (GLP-1) receptor agonists have on weight loss have recently generated interest and investigation. Semaglutide activates GLP-1 receptors, improving incretin function and insulin secretion (glucose-dependent), inhibiting glucagon release and suppressing hepatic gluconeogenesis, resulting in reductions in both fasting as well as postprandial glucose, they wrote in Cardiovascular Drugs and Therapy
Tirzepatide has not been adequately studied in pregnant women, making its safety profile during pregnancy unknown
Building on these findings, Lincoff et al
It has a boxed warning for thyroid C-cell tumors and other safety considerations
TRIUMPH-1 and TRIUMPH-2 results will answer this